acute myeloid leukemia (AML) | Aplastic Anemia & MDS International Foundation

acute myeloid leukemia (AML)

Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT

This is a Phase 1, open-label, non-randomized, single and multiple dose escalation study designed to evaluate the safety and preliminary efficacy (prevention of, or treatment of relapse) of administering Mana 312 to subjects with AML/MDS after allogeneic HSCT. The study will evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of single and multiple doses of Mana 312. Each cycle of administration of Mana 312 will be 28 days.

Martha L. Arellano, MD

Arellano, Martha
Associate Professor, Department of Hematology and Medical Oncology
Emory University

Martha L. Arellano, MD, is an Associate Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine where she serves as Associate Director of the Division of Hematology. Board certified in hematology, medical oncology and internal medicine, Dr. Arellano specializes in the treatment of leukemia and

2021 March for Marrow California - Virtual Walk and 5K

Help us continue to support the patients served by AAMDSIF by registering to run in our 2021 Virtual Walk and 5K or simply by donating. We look forward to walking and running with you the week of April 24 - May 1, 2021, and continuing the celebration of the brave patients and families that are fighting

Event Date: 
Sat, 04/24/2021 to Sat, 05/01/2021
Community Event Type: